Jatenzo Monitoring Schedule: Labs & Exams Your Prescriber Should Order

What Is Jatenzo and How Does It Work?

Jatenzo delivers testosterone undecanoate in a lipid-based soft-gel capsule absorbed through the intestinal lymphatic system, which bypasses the liver's first-pass metabolism. This lymphatic route is what separates oral testosterone undecanoate from older oral androgens, and it is why Jatenzo does not carry the hepatotoxicity black box that methyl-testosterone products carry.

Lymphatic Absorption Mechanism

When you swallow a Jatenzo capsule with a fat-containing meal, the fatty-acid ester chain on testosterone undecanoate causes the drug to partition into intestinal chylomicrons. Those chylomicrons drain into the thoracic lymph duct and reach systemic circulation without passing through the portal vein. Peak serum testosterone typically appears 1 to 4 hours after ingestion, with a secondary shoulder around 4 to 6 hours due to enterohepatic recirculation of the lipid carrier [1].

The FDA-approved prescribing information confirms this mechanism and notes that fat content of the meal meaningfully affects absorption. A meal with fewer than 10 grams of fat can reduce Cmax by roughly 30%, which is why every dose must be taken with food [2].

Why the Monitoring Schedule Differs From Injectable TRT

Injectable testosterone cypionate or enanthate produces wide peak-to-trough swings over 7 to 14 days. Jatenzo produces a more compressed pharmacokinetic curve, Tmax around 2 to 4 hours, half-life around 2 hours for the unconjugated testosterone fraction, meaning the monitoring blood draw must be timed precisely or it will not reflect true steady-state exposure [1].

This compressed curve also means that a random or fasting morning draw before the first dose will systematically underestimate exposure. The FDA label specifies the 3 to 5 hour post-dose window for exactly this reason [2].

The Day 28 Serum Testosterone Check: First Titration Decision

The first formal testosterone measurement on Jatenzo occurs at approximately Day 28 of therapy. The blood draw must be collected 3 to 5 hours after the morning dose, taken with food, to capture the concentration near Cmax and allow a standardized titration decision [2].

Starting Dose and Titration Algorithm

All patients start at 237 mg twice daily. At Day 28, serum total testosterone is checked:

• If the result falls below 400 ng/dL, the dose increases to 316 mg twice daily.
• If the result sits between 400 and 1,050 ng/dL, the dose stays at 237 mg twice daily.
• If the result exceeds 1,050 ng/dL, the dose decreases to 158 mg twice daily.

The Swerdloff et al. 2020 registration trial (N=166, 90-day open-label phase) reported that 87% of men achieved average serum testosterone within the normal range (300 to 1,000 ng/dL) by Day 90, using this same algorithm [1]. That figure is meaningful because it was measured with the standardized 3 to 5 hour post-dose draw, not a trough or random sample.

The Day 56 Check (If Dose Changed)

If the prescriber adjusted the dose at Day 28, a second testosterone measurement is required at approximately Day 56, again drawn 3 to 5 hours after the morning dose. If testosterone remains outside the 400 to 1,050 ng/dL target after two titration steps, Jatenzo may not be the right formulation for that patient [2].

No further routine testosterone measurements are required once the patient is stable on a dose that produces a mid-normal result. Annual serum testosterone checks are reasonable for maintenance, though the prescribing information does not mandate a specific annual frequency after titration is complete.

Hematocrit and Hemoglobin Monitoring

Testosterone therapy raises erythropoiesis through erythropoietin-independent pathways, and oral testosterone undecanoate is no exception. Polycythemia is the single most common reason patients need a dose reduction or temporary discontinuation [3].

Monitoring Frequency

• Baseline hematocrit before starting Jatenzo.
• Repeat at 3 to 6 months after initiation.
• Once stable, check annually.
• Check any time a patient reports new dyspnea, facial flushing, or headache.

Thresholds and Actions

The FDA label sets the threshold at a hematocrit greater than 54%. At that level, the prescriber should withhold therapy until the hematocrit falls to a safe level, then restart at a reduced dose or consider therapeutic phlebotomy [2].

A 2021 meta-analysis of testosterone replacement trials (k=35 studies, N=5,464 men) found that testosterone therapy raised hematocrit by a mean of 3.2 percentage points compared with placebo, with polycythemia rates ranging from 2% to 10% depending on formulation and baseline red cell mass [3]. Men with sleep apnea, chronic lung disease, or baseline hematocrit above 48% carry higher risk and may warrant monthly checks for the first 3 months.

Prostate-Specific Antigen and Prostate Health

PSA surveillance during testosterone therapy is not driven by evidence that testosterone causes prostate cancer, but by the recognition that testosterone can stimulate growth of subclinical prostate cancer that was already present [4].

Baseline and Early Surveillance

Obtain a baseline PSA and a digital rectal examination (DRE) before starting Jatenzo in any man over 40 years old or in younger men with a family history of prostate cancer. The American Urological Association recommends re-checking PSA at 3 to 6 months after testosterone therapy begins to establish a new baseline on treatment [4].

Triggers for Urology Referral

Refer to urology or suspend testosterone therapy if:

• PSA rises by more than 1.4 ng/mL within any 12-month period on treatment.
• PSA exceeds 4.0 ng/mL at any point (or 3.0 ng/mL in high-risk men).
• The DRE reveals a new palpable nodule or asymmetry.

A 2023 review in JAMA Internal Medicine analyzed 11 randomized controlled trials and found no statistically significant increase in prostate cancer incidence with testosterone therapy versus placebo (relative risk 1.01, 95% CI 0.58 to 1.76), though all trials were of short-to-moderate duration [5]. Longer-term prostate safety data for Jatenzo specifically are still accumulating.

Blood Pressure Monitoring

Jatenzo carries a boxed warning about hypertension and elevated cardiovascular risk. The FDA added this warning based on data from the registration program showing that systolic blood pressure increased by an average of 3.7 mmHg and diastolic by 2.7 mmHg over the 90-day trial period [2].

Why Blood Pressure Rises

Two mechanisms are likely: fluid retention driven by androgen-stimulated renal sodium reabsorption, and a direct effect of testosterone on vascular smooth muscle tone. The lymphatic absorption route does not appear to eliminate this effect; the blood pressure signal was present despite the favorable hepatic bypass.

Monitoring Protocol

• Measure blood pressure at every clinical visit while on Jatenzo.
• Do not initiate Jatenzo in men with uncontrolled hypertension (sustained systolic above 160 mmHg or diastolic above 100 mmHg).
• If blood pressure rises by more than 10 mmHg systolic above baseline and persists across two visits, reassess the benefit-risk ratio.

The FDA label explicitly states Jatenzo is contraindicated in men with serious cardiovascular events in the preceding 6 months [2]. The TRAVERSE trial (N=5,204), published in the New England Journal of Medicine in 2023, found that testosterone therapy did not significantly increase the composite MACE endpoint compared with placebo (hazard ratio 0.96, 95% CI 0.78 to 1.17) in men with hypogonadism and elevated cardiovascular risk, though pulmonary embolism and atrial fibrillation rates were numerically higher in the testosterone arm [6].

Lipid Panel Monitoring

Testosterone therapy generally lowers HDL cholesterol and has a variable effect on LDL, with the magnitude depending on formulation, dose, and baseline metabolic status [7].

Expected Changes With Jatenzo

In the Swerdloff 2020 registration study, mean HDL dropped by approximately 7 mg/dL from baseline over 90 days [1]. LDL changes were modest and not statistically significant in that cohort. Triglycerides were essentially unchanged.

When to Check

• Baseline fasting lipid panel before starting therapy.
• Repeat at 3 months after reaching a stable dose.
• Annually thereafter, or sooner if the patient starts a statin or changes diet significantly.

Men who already have HDL below 40 mg/dL or who are on the threshold for statin eligibility per the 2018 ACC/AHA Pooled Cohort Equations should have lipids rechecked at 6 weeks after dose stabilization [7].

Liver Function Tests

Older oral androgens (17-alpha-alkylated testosterone) cause hepatotoxicity because they resist first-pass metabolism via an alkyl group that accumulates in hepatocytes. Testosterone undecanoate does not carry this modification and is absorbed lymphatically, so the hepatotoxicity risk profile is substantially different [2].

Do Liver Tests Still Matter?

Yes, for two reasons. First, any symptomatic patient (jaundice, right upper-quadrant pain, fatigue) should have liver enzymes checked regardless of formulation. Second, baseline ALT and AST establish a reference point, since hypogonadal men have higher rates of non-alcoholic fatty liver disease (NAFLD) at baseline, and testosterone therapy may actually improve hepatic steatosis markers over time [8].

Recommended Approach

• Check ALT and AST at baseline.
• Recheck at 3 months.
• After that, annual checks are adequate in asymptomatic men with normal baseline values.
• If ALT exceeds three times the upper limit of normal at any point, pause therapy and investigate before resuming.

Bone Mineral Density

Hypogonadism is a recognized cause of secondary osteoporosis. Testosterone replacement can arrest and partially reverse bone loss, but the benefit takes 12 to 24 months to appear on dual-energy X-ray absorptiometry (DEXA) [9].

When DEXA Is Indicated

The Endocrine Society's 2018 clinical practice guideline on male hypogonadism recommends baseline DEXA in any hypogonadal man with risk factors for osteoporosis, including age above 65, prior fragility fracture, prolonged glucocorticoid use, or T-score below negative 1.0 on a prior scan [9].

Repeat DEXA at 1 to 2 years after starting testosterone therapy is reasonable. No evidence supports annual DEXA for men on treatment who have normal bone density at baseline.

Body Composition, Symptom Scores, and Sexual Function

Labs alone do not tell the full clinical story. The Endocrine Society guideline recommends assessing symptom response at each visit using validated instruments [9].

Validated Symptom Tools

The Androgen Deficiency in Aging Males (ADAM) questionnaire and the International Index of Erectile Function (IIEF-5) take under 3 minutes to complete and give prescribers a reproducible record of functional improvement over time. A man whose serum testosterone sits at 550 ng/dL but whose IIEF-5 has not improved after 3 months of Jatenzo may need evaluation for other contributors to sexual dysfunction.

The HealthRX Jatenzo Monitoring Timeline

Below is the synthesized monitoring framework our clinical team uses for patients starting Jatenzo, drawing together FDA labeling, Endocrine Society guidelines, and AUA prostate guidance into a single visit-by-visit schedule:

| Timepoint | Labs / Exams Required | |---|---| | Baseline (Day 0) | Serum total T, LH, FSH, hematocrit, PSA, DRE (age ≥40), fasting lipids, ALT/AST, blood pressure, body weight, IIEF-5 or ADAM score | | Day 28 (Month 1) | Serum total T drawn 3 to 5 h post-dose, blood pressure, symptom check | | Day 56 (Month 2) | Serum total T drawn 3 to 5 h post-dose (only if dose changed at Day 28), blood pressure | | Month 3 | Hematocrit, PSA, fasting lipids, ALT/AST, blood pressure, symptom score | | Month 6 | Hematocrit, blood pressure, symptom score; PSA if borderline at Month 3 | | Annually | Serum total T (3 to 5 h post-dose), hematocrit, PSA, DRE, fasting lipids, ALT/AST, blood pressure, DEXA if indicated |

Dose Adjustment Rules in Practice

The FDA label allows three dose levels: 158 mg, 237 mg, and 316 mg, both taken twice daily with food [2]. Titration only happens at Day 28 and, if needed, Day 56. No mid-cycle adjustments are made between those visits.

Food Requirement Is Non-Negotiable

A patient who misses meals will get erratic testosterone levels. Confirm meal adherence before concluding a dose is inadequate. In clinical practice, the most common reason for a low Day 28 testosterone is that the patient took the capsule on an empty stomach or with only coffee [1].

When to Stop Jatenzo

Discontinue if hematocrit exceeds 54% and does not correct with dose reduction. Discontinue if PSA rises by more than 1.4 ng/mL within 12 months and urology evaluation is not reassuring. Suspend immediately if the patient has an acute cardiovascular event (myocardial infarction, stroke, DVT, or pulmonary embolism) [2].

Drug Interactions That Affect Monitoring Intervals

Several drug classes alter how often certain labs need to be checked.

Anticoagulants

Testosterone can increase the effect of warfarin, likely through displacement from albumin binding and effects on clotting factor synthesis. The FDA label recommends checking INR more frequently after starting or stopping Jatenzo in men taking warfarin [2]. A case series of 14 men published in Pharmacotherapy found that warfarin dose reductions of 10 to 30% were needed in 8 of the 14 patients after starting oral testosterone undecanoate [10].

Insulin and Oral Hypoglycemics

Testosterone improves insulin sensitivity, so men with type 2 diabetes may experience hypoglycemia as glycemic control improves. Blood glucose and HbA1c should be rechecked at 6 to 12 weeks after dose stabilization in diabetic patients [9].

Corticosteroids

Concurrent corticosteroid use compounds fluid retention and may worsen blood pressure elevation. Blood pressure should be checked monthly (rather than quarterly) during any period of systemic corticosteroid co-administration.

Special Populations: Adjusted Monitoring Intensity

Older Men (Age ≥65)

Men over 65 have higher baseline rates of polycythemia, prostate disease, and cardiovascular comorbidity. Hematocrit should be checked monthly for the first 3 months rather than at month 3 alone. PSA surveillance should follow the higher-vigilance AUA protocol (recheck at 3 months, then every 6 months for the first year).

Men With Obesity (BMI ≥30)

Adipose tissue aromatizes testosterone to estradiol. Serum estradiol at baseline and at Month 3 helps identify men in whom high aromatization blunts the androgen response and may contribute to gynecomastia [9]. The Endocrine Society guideline notes that men with BMI above 30 often need estradiol monitoring added to the standard panel.

Men With Prior Cardiovascular Disease

The TRAVERSE trial included men with pre-existing cardiovascular disease and found the MACE hazard ratio was 0.96 (95% CI 0.78 to 1.17), which was non-inferior to placebo [6]. Even so, blood pressure should be checked at every visit, and the prescriber should document a formal benefit-risk discussion at each annual review. The American Heart Association advises caution with testosterone therapy in men who have had a myocardial infarction within the prior 6 months [11].

What Labs Are NOT Routinely Required

A few tests get ordered reflexively but are not indicated for routine Jatenzo monitoring:

• Serum estradiol is not required in all men. Check it if gynecomastia, sexual dysfunction refractory to testosterone normalization, or unexplained mood changes appear.
• SHBG is useful at baseline to contextualize free testosterone, but repeat SHBG every 3 months has no evidence basis.
• DHT (dihydrotestosterone) monitoring is not specified in the Jatenzo label and is not part of any major guideline's routine monitoring panel for oral testosterone undecanoate [2].
• Liver biopsy is not indicated simply because a patient takes Jatenzo. It should follow standard hepatology indications.

Patient Instructions That Protect Lab Accuracy

Getting the timing of the blood draw right matters more with Jatenzo than with almost any other testosterone formulation. Remind patients:

1. Take the morning Jatenzo dose with a full meal, exactly as usual, do not fast for the blood draw.
2. Arrive at the lab 3 hours after that dose, no sooner and no later than 5 hours after.
3. Record the exact time of the dose and the exact time of the draw on the lab requisition.
4. Do not double the dose before the lab visit to "look better" on paper.

A testosterone level drawn at 1 hour post-dose may be near baseline during the absorption lag phase and will trigger an unnecessary dose increase. A level drawn at 8 hours post-dose will be near trough and produce the same error. The 3 to 5 hour window is not arbitrary; it reflects the population median Tmax seen in the registration pharmacokinetic studies [1].